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Original Article

Triple Vectors Expand AAV Transfer Capacity
in the Retina
Andrea Maddalena,1,6 Patrizia Tornabene,1,6 Paola Tiberi,1 Renato Minopoli,1 Anna Manfredi,1,2
Margherita Mutarelli,1 Settimio Rossi,3 Francesca Simonelli,3 Jurgen K. Naggert,4 Davide Cacchiarelli,1,2
and Alberto Auricchio1,5
1Telethon

Institute of Genetics and Medicine (TIGEM), Pozzuoli 80078, Italy; 2Armenise/Harvard Laboratory of Integrative Genomics, TIGEM, Pozzuoli 80078, Italy; 3Eye

Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences, Second University of Naples, Naples 80121, Italy; 4The Jackson Laboratory, Bar Harbor, ME
04609, USA; 5Medical Genetics, Department of Advanced Biomedicine, Federico II University, Naples 80131, Italy

Retinal gene transfer with adeno-associated viral (AAV) vectors holds great promise for the treatment of inherited retinal
degenerations (IRDs). One limit of AAV is its transfer capacity
of about 5 kb, which can be expanded to about 9 kb, using dual
AAV vectors. This strategy would still not sufﬁce for treatment
of IRDs such as Usher syndrome type 1D or Alström syndrome
type I (ALMS) due to mutations in CDH23 or ALMS1, respectively. To overcome this limitation, we generated triple AAV
vectors, with a maximal transfer capacity of about 14 kb. Transcriptomic analysis following triple AAV transduction showed
the expected full-length products along a number of aberrant
transcripts. However, only the full-length transcripts are efﬁciently translated in vivo. We additionally showed that approximately 4% of mouse photoreceptors are transduced by triple
AAV vectors and showed correct localization of recombinant
ALMS1. The low-photoreceptor transduction levels might
justify the modest and transient improvement we observe in
the retina of a mouse model of ALMS. However, the levels of
transduction mediated by triple AAV vectors in pig retina
reached 40% of those observed with single vectors, and this
bodes well for further improving the efﬁciency of triple AAV
vectors in the retina.

INTRODUCTION
Inherited retinal degenerations (IRDs), with an overall global prevalence of 1/2,000,1 are a major cause of blindness worldwide. IRDs are
mostly monogenic and are caused by mutations in genes mainly expressed in retinal photoreceptors (PRs; rods and cones) and to a lesser
extent in retinal pigmented epithelium (RPE).2 To date, gene therapy
based on adeno-associated viral (AAV) vectors represents the most
promising therapeutic approach for IRDs. AAVs are (1) safe and
effective when delivered subretinally in patients with Leber congenital
amaurosis type 2, a severe form of inherited childhood blindness3–8
and (2) to date, the most effective gene transfer vector for PRs in
addition to RPE.9–15 However, the relatively small DNA packaging
capacity of AAV, which is considered to be restricted to the size of
the parental genome (4.7 kb),16–19 prevents its application from the
treatment of those IRDs caused by mutations in genes having a coding
sequence (CDS) larger than 5 kb, such as Stargardt disease (STGD1;
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MIM_248200), Usher syndrome types IB (USH1B; MIM_276900)
and 1D (USH1D; MIM_601067), or Alström syndrome (ALMS;
MIM_203800), among others.
Dual AAV vectors20–23 have been developed to overcome the limitedcargo capacity of AAV by splitting a large transgene expression
cassette in two separate halves, each independently packaged in a single normal-size (<5 kb) AAV vector.20,21,23,24 The reconstitution of
the full-length expression cassette is achieved upon co-infection of
the same cell by both dual AAV vectors followed by inverted terminal
repeat (ITR)-mediated tail-to-head concatemerization of the 50 and 30
genomes and/or followed by splicing (dual AAV trans-splicing vectors [TS]);20–22,25 homologous recombination between overlapping
regions contained in both the 50 and 30 genomes (dual AAV overlapping vectors)21 or a combination of the two (dual AAV hybrid vectors), where the directional concatemerization can be favored by
the presence of highly recombinogenic sequences.23 We have recently
shown that both dual AAV TS and hybrid AK vectors (that contain
the short AK recombinogenic region from the F1 phage) efﬁciently
transduce mouse PRs and RPE, and rescue mouse models of
STGD1 and USH1B26 caused by mutations in ABCA4 (ATP-binding
cassette subfamily A member 4; CDS, 6.8 kb) and MYO7A (MYOSIN
VII A; CDS, 6.6 kb), respectively. Robust MYO7A reconstitution by
dual AAV vectors was conﬁrmed in the mouse retina by Dyka
et al.,27 while several examples of dual AAV systems for minidystrophin (CDS, 6.2 kb) expression in mouse muscle are available.23,28 The
efﬁcacy of dual AAV vectors, with a maximum transfer capacity of
around 9 kb, opens the venue for further expansion to triple AAV vectors with a theoretical transfer capacity of around 14 kb.
Triple AAV vectors, in principle, would enable the development of
gene therapies for IRDs due to mutations in genes whose CDS is
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Figure 1. Schematic Representation of Single and Triple AAV Vectors
Single ED-AAV (A); triple ED-AAVs (B); triple CDH-AAVs (C); triple ALMS-AAVs (D). The position of the epitopes recognized by the antibodies used in this study is indicated.
The vector genome size is depicted above each vector. bGHpA, bovine growth hormone polyadenylation signal; SD, splicing donor signal; SA, splicing acceptor signal; AP,
alkaline phosphatase recombinogenic region; AK, F1 phage recombinogenic region; AB200, ABCA4 recombinogenic region; 3xflag, triple flag tag; CMV, cytomegalovirus;
a-EGFP, anti-EGFP antibodies; a-3xflag, anti-3xflag antibodies; a-CDH23, anti-CDH23 antibodies; a-ALMS1, anti-ALMS1 antibodies.

larger than 9 kb (herein referred to as large genes). Among those IRDs
are (1) USH1D, a severe form of autosomal recessive blindness-deafness which accounts for 19%–35% of cases of Usher syndrome
type 129–31 and which is caused by mutations in CDH23 (CDS,
10.1 kb), which encodes for the Cadherin-related family member
2332,33 and (2) ALMS, an autosomal recessive condition, with a prevalence of less than one per million34, and characterized by a combination of features including obesity, insulin resistance, and retinal
dystrophy. ALMS is caused by mutations in ALMS1 (CDS, 12.5 kb),
which encodes for a ciliary/centrosomal protein thought to play a
key role in transport along the PR axoneme.34–38 Triple AAV vectors
have previously been exploited to reconstruct full-length dystrophin
(CDS, 11.1 kb) in the muscle of dystrophic mice.39,40 Low levels of
full-length dystrophin expression were obtained by both TS40 and
hybrid systems.39 These results demonstrated great potential for
testing triple AAV vectors in the retina to restore CDH23 and
ALMS1 gene expression. Indeed, the enclosed and small subretinal
space should favor co-infection and transduction of the same cell
by three independent AAV vectors.

RESULTS
Generation of Single and Triple AAV Vectors

In order to test transduction efﬁciency mediated by triple AAV
vectors, we generated a reporter protein by fusing the CDS
of EGFP to that of Discosoma red ﬂuorescent protein (DsRed)
(herein referred to as ED) separated by a 13 amino acid spacer.
A triple ﬂag tag (3xﬂag) was added at the 30 end of ED CDS
(Figure 1A), which was placed under the control of (1) the
ubiquitous cytomegalovirus (CMV) promoter, (2) the PR-speciﬁc
human interphotoreceptor retinoid-binding protein (IRBP) promoter,41,42 or (3) the RPE-speciﬁc vitelliform macular dystrophy 2
(VMD2) promoter.43 The ED cassettes were either packed in
a single AAV vector or split in three parts, each packed in a
different AAV vector (Figure 1B and Materials and Methods)
from here called ED-AAV 1, ED-AAV 2, ED-AAV 3. Upon
HEK293 transfection with plasmids expressing ED, the ED spontaneous ﬂuorescence appeared weaker than the ﬂuorescence detected
when single EGFP- or single DsRed-expressing plasmids were used
(Figure S1).
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Figure 2. Triple ED-AAV Vectors Efficiently Transduce ED In Vitro
(A and B) Western blot (WB) analysis of lysates from HEK293 cells either transfected with pED or infected with triple AAV2/2 vectors encoding for ED and stained with a-3xflag
(A) and a-EGFP (B) antibodies. The arrows on the right indicate the following protein products: #A, ED full-length protein; #B, from AAV 2 + 3; #C, from AAV 1 + 3; #F, from
AAV 3; #D and #E, aggregates of AAV 3. a-3xflag, WB with anti-3xflag antibodies; a-EGFP, WB with anti-EGFP antibodies; a-b-Tubulin, WB with anti-b-Tubulin antibodies,
used as loading control. Neg, not infected cells. The molecular weight ladder is depicted on the left; 20 and 200 mg of proteins for transfected and infected samples,
respectively, were loaded. The WB images are representative of n = 4 independent experiments. (C) Fluorescent analysis of HEK293 cells infected with triple AAV2/2 vectors
encoding for ED. The scale bar (200 mm) is depicted in the figure. DsRed, Discosoma red fluorescent protein; Merge: overlay of EGFP and DsRed images.

Similarly, CDH23-3xﬂag and ALMS1-3xﬂag were split in three parts
each cloned in a separate AAV vector (Figures 1C and 1D and Materials and Methods) from here called CDH-AAV 1, CDH-AAV 2,
CDH-AAV 3, and ALMS-AAV 1, ALMS-AAV 2, ALMS-AAV 3.
CDH-AAV 1 and ALMS-AAV 1 included the ubiquitous CMV and
either the short CMV (shCMV) or the PR-speciﬁc human G protein-coupled receptor kinase 1 (GRK1) promoters, respectively.
For the in vitro experiments, we generated AAV2/2 vectors, which
efﬁciently transduce HEK293 cells.44 In the experiments performed
in the mouse and pig retinas, we used AAV2/8 vectors, which
efﬁciently transduce RPE and PRs9–11 but poorly infect HEK293 cells.
Triple ED-AAV Vectors Efficiently Transduce HEK293 Cells

First, we evaluated the efﬁciency of triple ED-AAV-mediated
large gene transduction in vitro by infecting HEK293 cells with
AAV2/2 vectors at an MOI of 5  104 genome copies (GC)/cell
of each vector. Seventy-two hours after infection, cell lysates were
analyzed and the ED expression was evaluated by western blot
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(WB) using anti-3xﬂag (Figure 2A) or anti-EGFP (Figure 2B) antibodies (please see their speciﬁc epitope localization in Figure 1), by
direct microscope imaging (Figure 2C) and by cytoﬂuorimetry. As
shown in Figures 2A and 2B, full-length proteins (#A) of the expected size (z60 kDa) were detected only following co-infection
with the three ED-AAV vectors. Various shorter products were detected by the anti-3xﬂag antibodies when ED-AAV 3, which includes
the 3xﬂag tag, was added to the infection mix (Figure 2A). These
include (1) a product that derives from ED-AAV 2 + 3 (#B); (2) a product that might derive from the concatemerization of ED-AAV 1 + 3
and the use of an alternative ATG in frame with the 3xﬂag (#C);
(3) a product from ED-AAV 3 alone (#F); and (4) products that
might represent aggregates of #F (#D and #E). WB with anti-EGFP
antibodies (Figure 2B) conﬁrmed the presence of both full-length
ED (#A) when the 3 ED-AAV vectors were used and the shorter #B
product in the ED-AAV 2 + 3 sample. Interestingly, the relative
amount of the truncated products decreases when the 3 ED-AAV vectors are used.

www.moleculartherapy.org

ED expression was also evaluated by direct imaging of native ﬂuorescence (Figure 2C). Double EGFP and DsRed-positive cells could be
detected only when the 3 ED-AAVs were used. Cells that are positive
for either EGFP or DsRed alone were detected when ED-AAV 1 + 2 or
ED-AAV 2 + 3 were respectively used, but they were almost absent in
the ED-AAV 1 + 2 + 3 samples.
The efﬁciency of triple ED-AAVs transduction was then quantiﬁed by
cytoﬂuorimetry, which showed that double EGFP and DsRed-positive
cells were present above background only in single ED-AAV
(46.69% ± 5.66%; n = 4) and in ED-AAV 1 + 2 + 3 (2.78% ±
0.84%; n = 3) samples. Therefore, the efﬁciency of triple ED-AAVs
transduction is 5.96% ± 1.95% of that of the corresponding single
vector.
Triple CDH- and ALMS-AAV Vectors Efficiently Transduce
HEK293 Cells

HEK293 cells were infected with the various combinations of CDHand ALMS-AAV2/2 vectors at an MOI of 5  104 GC/cell and
analyzed 72 hr post-infection. The expression of full-length and truncated products of CDH23 and ALMS1 was evaluated at both transcriptional and translational levels.
cDNAs from HEK293 infected cells were analyzed by real-time qPCR.
For each transgene, six primers (A/F) were used, each annealing to
one extremity of the three CDSs separately included in each of the triple vectors (Figure 3A). First, we observed that the real-time qPCR
ampliﬁcation using primers D (located at the 30 end of vector 2)
and E (located at the 50 of vector 3) following infection with
AAV 2 + 3 is signiﬁcantly lower than the one obtained when
AAV 1 + 2 + 3 are used (2% for CDH23 and 20% for ALMS1). This
means that ampliﬁcation with this set of primers can be used as a close
estimate of full-length transcript following concatemerization of the
three vectors. For simplicity, from now on, such measurement will
be set to 1 as reference, and the abundance of the other products
will be presented as fold change relative to the reference. To detect
the transcripts from all possible triple AAV concatemers, the A/F
primers were tested in all possible combinations. The sets of primers
that generated a PCR product with a relative abundance >0.1
compared to full-length are reported in Figure 3B, along with a schematic representation of the corresponding predicted AAV concatemer. For both CDH23 and ALMS1 transgenes, ampliﬁcation of
products with a relative abundance higher than full-length was obtained with the following primer couples: B + C, A + B, B + E, and,
only in the case of ALMS1, C + D (shown in bold in Figure 3B,
“in vitro” column). Direct sequencing of real-time qPCR products revealed that, upon correct assembly of the triple CDH- or ALMS-AAV,
correct splicing occurs (data not shown).
As the real-time qPCR analysis cannot reveal the generation of alternative splicing within the three CDSs, we additionally performed a
targeted RNA-seq analysis with de novo annotation of the two transgenes. The analysis annotated the presence of the full-length transcript in both CDH23 (Figure S2A) and ALMS1 (Figure S2B) samples.

Similar to what we observed in the real-time qPCR analysis, the most
represented products derive from the concatemerization of AAV 1 +
3. It is interesting to note that the CDS of CDH-AAV 3 seems to
generate several isoforms as a consequence of alternative splicing.
Following detailed transcriptional characterization of HEK293 cells
infected with triple AAV vectors, we tested the presence of full-length
and truncated CDH23 and ALMS1 protein products. WB analysis of
lysates from infected cells was performed using antibodies (please see
their speciﬁc epitope localization in Figure 1) directed to either the
3xﬂag tag (Figures 4A and 4C) or CDH23 and ALMS1 (Figures 4B
and 4D). In all cases, full-length protein (#A) was detected with
both anti-3xﬂag and anti-CDH23 or anti-ALMS1 antibodies only
when the three CDH- (Figures 4A and 4B; z360 kDa) or ALMSAAVs (Figures 4C and 4D; z461 kDa) were used. Please note that
the shape of the ALMS1 bands in the lanes ALMS-AAV 1 + 2 + 3
may be due to the challenging migration of such high molecular
weight proteins in the SDS-PAGE. In addition to the full-length proteins, several shorter products were observed: (1) a truncated product
(#B) which corresponds to CDH23 C terminus was detected with
anti-3xﬂag antibodies when CDH-AAV 3 was included in the infection mix (Figure 4A); (2) only in the sample infected with CDHAAV 1 + 3, a smear of bands was observed that was greatly reduced
when the three CDH-AAV vectors were included in the infection mix
(Figure 4A); (3) a truncated product of z270 kDa (#B) was detected
with anti-3xﬂag antibodies when ALMS-AAV 1 + 3 was included in
the infection mix (Figure 4C). The two bands of z171 and
z117 kDa present in all lanes of the WB shown in Figure 4D are presumably due to aspeciﬁc antibody binding.
Subretinal Administration of Triple ED-AAVs Results in FullLength Transgene Expression in Mouse and Pig Retina

We hypothesized that the enclosed and small subretinal space should
favor co-infection and transduction of the same cell by three independent AAV vectors. To evaluate this, we injected subretinally triple
CMV-ED-AAV2/8 vectors (dose of each vector/eye, 4.2  109 GC)
in 4-week-old C57BL/6J mice (n = 7 eyes). Eyes were harvested
2 months later, and we analyzed, on retinal cryosections, the number
of PR cells expressing ED (Figure 5A). We found, in the transduced
area of 5 out of 7 eyes, that 2.9% ± 0.5% were positive for EGFP alone
(which derives from concatemerization of only ED-AAV 1 + 2) and
3.6% ± 0.3% were positive for both EGFP and DsRed (which derives
from concatemerization of ED-AAV 1 + 2 + 3). As no PRs were positive for DsRed alone (which derives from ED-AAV 2 + 3), we
conclude that the co-expression of EGFP-DsRed indicates full-length
protein expression deriving from proper directional concatemerization of ED-AAV 1 + 2 + 3.
To conﬁrm by WB analysis the retinal expression of full-length
ED protein as well as to detect potential byproducts from EDAAV 1 + 3 that could not be viewed on retinal histological sections,
the following combinations of triple ED-AAVs (dose of each
vector/eye, 4.2  109 GC) were injected subretinally in 4-week-old
C57BL/6J mice: ED-AAV 1 + 2 + 3 (n = 8 eyes); ED-AAV 2 + 3
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Figure 3. Transcriptomic Analysis following Transduction with Triple AAV Vectors
(A) Schematic representation of triple CDH and ALMS-AAV vectors with primers used for real-time qPCR (A/F). Prom, promoter; CDS, coding sequence; polyA, polyadenylation signal; 3xflag, triple flag tag; SD, splicing donor signal; SA, splicing acceptor signal; rec, recombinogenic region. (B) Results of the real-time qPCR analysis
performed on cDNAs from HEK293 cells or mouse eyecups treated with either CDH- or ALMS-AAV 1 + 2 + 3 vectors. The left column shows the vector assembly predicted
on the basis of the set of primers used. The two columns on the right show the abundance of the PCR products relative to full-length detected by the D + E primers. Only
products with a relative abundance >0.1 are shown. Highlighted in italic is the relative abundance of PCR products resulting from the desired AAV directional concatemerization. Highlighted in bold are the PCR products with a relative abundance >1.

(n = 8 eyes); ED-AAV 1 + 3 (n = 6 eyes); ED-AAV 3 (n = 6 eyes);
single ED-AAV (n = 6 eyes). Eyecups were harvested 2 months
later, and WB analysis was performed using anti-3xﬂag antibodies.
As shown in Figure 5B, apart from the full-length protein (#A),
when the 3 ED-AAV vectors were included in the mix, an additional
faint band of lower molecular weight was detected (#C), which has a
molecular weight similar to that detected in vitro in the ED-AAV
1 + 3 sample (#C) (Figure 2A). However, this product was present
only in one out of six eyes injected with ED-AAV 1 + 3, conﬁrming
that this is a rare event which was not detected in retinal histological
sections (Figure 5A). The other bands present in ED-AAV 1 + 2 + 3
sample, which are also present in the samples injected with single
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ED-AAV, might represent degradation products of the full-length
ED protein.
We then investigated whether triple AAV transduction occurs in
different retinal cell types. Toward this end, 4-week-old C57BL/6J
mice were injected subretinally with three sets of triple ED-AAV vectors, each with a different promoter: CMV, IRBP, and VMD2 at the
doses of 4.2  109, 3.7  109, and 2.4  109 GC/each vector/eye,
respectively. Animals were sacriﬁced 2 months post-injection, and
protein lysates from eyecups were analyzed by WB, which showed
that full-length ED reconstitution and expression can be driven by
all three promoters, although with different efﬁciencies. Subretinal
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Figure 4. Triple CDH- and ALMS-AAV Vectors Efficiently Transduce CDH23 and ALMS1 In Vitro
(A and B) WB analysis of lysates from HEK293 cells infected with triple AAV2/2 vectors encoding for CDH23 and incubated with either anti-3xflag (A) or anti-CDH23 (B)
antibodies. The arrows on the right indicate the following protein products: #A, full-length CDH23 protein; #B, from AAV 3. (C and D) WB analysis of lysates from HEK293 cells
infected with triple AAV2/2 vectors encoding for ALMS1 and incubated with either anti-3xflag (C) or anti-ALMS1 (D) antibodies. The arrows on the right indicate the following
protein products: #A, full-length ALMS1 protein; #B, from AAV 1 + 3. a-3xflag, WB with anti-3xflag antibodies; a-CDH23, WB with anti-CDH23 antibodies; a-ALMS1, WB
with anti-ALMS1 antibodies; a-Filamin A, WB with anti-Filamin A antibodies, used as loading control. Neg, cells infected with control AAV2/2-CMV-EGFP vectors. The
molecular weight ladder is depicted on the left, 100 (A), 250 (B), or 200 mg (C and D) of proteins were loaded.

injection of triple VMD2-ED-AAV vectors, which includes the RPEspeciﬁc VMD2 promoter, displayed strong protein expression in
10/10 analyzed eyes. The ubiquitous CMV promoter resulted in
slightly higher levels of ED expression compared to VMD2 in 13/18
(72%) analyzed eyes. The IRBP promoter, speciﬁc for PR expression,
resulted in faint ED expression in 14/19 (74%) analyzed eyes
(Figure 5C).
To assess if the weak PR transduction observed with the IRBP promoter was due to poor transcriptional activity of the promoter in the
PRs or limited recombination upon co-infection of the three vectors,
we compared the expression of the ED protein encoded by the triple
AAV vectors to the expression by a single AAV vector containing
the same expression cassette (Figures 5D and 5E; Figures S3 and
S4). The experiment was performed with both the CMV (Figures
5D and S3) and IRBP (Figures 5E and S4) promoters, and ED protein expression was evaluated by WB analysis with anti-3xﬂag anti-

bodies. WB band intensity showed that, in the case of the CMV
promoter, the level of ED expression obtained with the triple AAV
vectors was 27% ± 6% of the one obtained with the single AAV
vector (n of eyes injected with single AAV = 12; n of eyes injected
with triple AAVs = 14), while this decreased to 2% ± 1% when
IRBP promoter was used (n of eyes injected with single AAV = 6;
n of eyes injected with triple AAVs = 8), thus suggesting that multiple AAV transduction, rather than the promoter strength, impacts
on mouse PR transduction, as also previously observed with dual
AAV vectors.45
We then evaluated the efﬁcacy of the triple ED-AAV vectors at transducing PRs in the pig retina. The pig retina is an excellent model to
evaluate viral vector transduction characteristics because of its size,
which is similar to the human retina, and because it is enriched
with cones that are concentrated in a streak-like region similar to
what happens in the primate macula.10 We injected subretinally Large
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Figure 5. Triple AAV Vectors Drive Full-Length Protein Expression in the Mouse Retina
(A) Fluorescence analysis of retinal cryosections from C57BL/6J mice 2 months following subretinal injection of triple ED-AAV2/8 vectors under the control of the ubiquitous
CMV promoter. The pictures with insets at higher magnification are representative of n = 5 injected eyes. Full arrows indicate EGFP and DsRed double-positive PRs. Dashed
arrows indicate EGFP-only positive PRs. The scale bar (20 mm) is depicted in the figure. DsRed, Discosoma red fluorescent protein; Merge, overlay of EGFP, DsRed, and DAPI
images; RPE, retinal pigmented epithelium; ONL, outer nuclear layer. (B) Western blot (WB) analysis of truncated products in eyecup lysates from C57BL/6J mice 2 months
following subretinal injection of the combinations of ED-AAVs. The arrows indicate the following products: #A, ED full-length protein; #C, from AAV 1 + 3. (C) WB analysis of
lysates from C57BL/6J eyecup 2 months following subretinal injection of triple AAV2/8 vectors encoding for ED under the control of the ubiquitous CMV, the RPE-specific
VMD2, and the PR-specific IRBP promoters. The arrow indicates the full-length protein. (D) WB analysis of eyecup lysates from C57BL/6J mice 2 months following subretinal
injection of single and triple AAV2/8 vectors encoding for ED under the control of the ubiquitous promoter CMV. (E) WB analysis of eyecup lysates from C57BL/6J mice
2 months following subretinal injection of single and triple AAV2/8 vectors encoding for ED under the control of the PR-specific promoter IRBP. CMV, cytomegalovirus; VMD2,
vitelliform macular dystrophy 2; IRBP, human interphotoreceptors retinoid binding proteins. a-3xflag, WB with anti-3xflag antibodies; Ponceau, staining with Ponceau, used
as loading control; a-b-Tubulin, WB with anti-b-Tubulin antibodies, used as loading control. Neg, lysates of eyecups following injection with PBS. The molecular weight ladder
is depicted on the left; 100 (D), 150 (B and C), and 200 (E) mg of proteins were loaded.

White pigs with single and triple AAV2/8 vectors encoding ED protein under the transcriptional control of the PR-speciﬁc promoter
IRBP (dose of each vector/eye, 1  1011 GC), and found two out of
three positive eyes in both groups. WB band intensity quantiﬁcation
showed that ED protein expression with triple AAV vectors was
39% ± 17% (n = 2) of that observed with a single AAV vector (Figure 6A). Moreover, no truncated products were detected by WB
analysis with anti 3xﬂag antibodies of neural retina lysates following
subretinal injection of ED-AAV 1 + 2 + 3 (Figure 6B). A shorter
product was observed in the ED-AAV 1 + 3 sample (#E), which is
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similar to the one observed in infected cells (#E) (Figure 2A). Overall,
these data suggest that triple AAV vectors transduce pig PRs more
efﬁciently than mouse, as previously observed with dual AAV
vectors.26
Expression of Therapeutic Transgenes Mediated by Triple AAV
Vectors in the Mouse Retina

We then tested whether subretinal administration of triple AAV2/8
vectors results in expression of CDH23 and ALMS1, which are both
mutated in syndromic forms of retinitis pigmentosa.32–37

www.moleculartherapy.org

Then, the RNA population emerging following triple AAVs subretinal administration was analyzed by real-time qPCR using primer
sets which were previously shown to amplify in vitro transcripts
with a relative abundance >0.1 of full-length (Figure 3B, “in vitro” column). Among them, the following primer resulted in ampliﬁcation of
transcripts with a relative abundance higher than full-length: A + B,
A + D, B + C, B + E, C + D, and, only for ALMS1, B + D and
E + F (shown in bold in Figure 3B, “mouse retina” column).
To understand which of these transcripts were translated to detectable levels, WB analysis of injected retinas was performed using
anti-3xﬂag antibodies: a faint but consistent band corresponding
to full-length protein was detected in 11 out of 15 eyes and in 5
out of 8 eyes injected with either CDH- (Figure 7A) or ALMSAAVs, respectively (Figure 7B). A shorter product was observed
in the CDH23 sample (#C), which is similar to the most intense
band present in the CDH-AAV 1 + 3 sample in vitro (Figure 4A).
No truncated products were observed by WB in retinas injected
with triple ALMS-AAVs. Immunohistochemistry (IHC) analysis of
retinal cryosections following subretinal injections with triple
CDH-AAVs conﬁrmed expression in PRs (data not shown).
A similar analysis was performed with the set of triple ALMSAAV vectors used to rescue the retina of ALMS mice (see next paragraph and Figure 8A).
Subretinal Administration of Triple AAV Vectors in ALMS Mice
Figure 6. Triple AAV Vectors Drive Full-Length Protein Expression in the Pig
Retina
(A) Western blot (WB) analysis of lysates from Large White pig retina 2 months
following subretinal injection of either single or triple AAV2/8 vectors encoding for ED
under the control of the PR-specific promoter IRBP. The arrow indicates the fulllength protein. (B) WB analysis of truncated products in lysates from Large White pig
retina 2 months following subretinal injection of the combinations of triple ED-AAVs.
Lysates of HEK293 cells infected with an ED-AAV 1 + 2 + 3 are shown on the left as
positive control. The arrows indicate the following products: #A, ED full-length
protein; #E, probably from AAV 3. a-3xflag, WB with anti-3xflag antibodies;
a-b-Actin, WB with anti-b-Actin antibodies, used as loading control. Neg, lysates of
retinas following injection with PBS. The molecular weight ladder is depicted on the
left; 200 mg of proteins were loaded.

We injected subretinally 4-week-old C57BL/6J mice with either triple
CMV-CDH-AAV (dose of each vector/eye, 2  109 GC) or triple
shCMV-ALMS-AAV vectors (dose of each vector/eye, 2  109 GC).
Animals were sacriﬁced 2 to 3 months post-injection, and transgene
expression was evaluated by both real-time qPCR and WB. Under the
assumption that the PCR product ampliﬁed with the D + E primer
couple derives mostly from full-length transcripts, we compared the
levels of triple AAV-mediated transgene expression to endogenous.
We found that transgenic CDH23 and ALMS1 were 102% ± 55%
and 7% ± 2% of endogenous, respectively (n = 3 eyes/each group).
The apparently different levels of CDH23 and ALMS1 transgene
expression result from different levels of their corresponding endogenous transcripts: indeed, endogenous CDH23 is less expressed
(0.005% ± 0.002% of glyceraldehyde 3-phosphate dehydrogenase
[GAPDH]) than endogenous ALMS1 (0.22% ± 0.02% of GAPDH).

Retinal thickness and electrophysiological responses of Alms1/
were both reduced compared to littermate control (Alms1/+ or
wild-type) mice starting around 4–6 months (data not shown),
similar to what observed in other Alms1/ models.46,47
To test whether the levels of PR transduction obtained with triple
AAV vectors are therapeutically relevant, we have generated triple
ALMS-AAV vectors that include the GRK1 promoter, which restricts
transgene expression to PRs, where ALMS1 is known to localize.48,49
Subretinal injection of these vectors (dose of each vector/eye, 2  109
GC) in 4-week-old C57BL/6J mice results in ALMS1 proper PR
localization 2 months after injection (Figure 8A). We can infer
that transgenic ALMS1 staining derives from full-length protein, as
ALMS1 potential localization signal is predicted to be at the N terminus of the protein50 while the 3xﬂag tag at the C terminus, and
transcripts from ALMS-AAV 1 + 3 would be out of frame. Triple
GRK1-ALMS-AAV vectors were then injected subretinally in
4-week-old Alms1/ mice,51 which received PBS in the contralateral
eye. Four months post-injection, we evaluated by real-time qPCR the
expression of transgenic ALMS1 transcript and found that this was
8.1% ± 6.6% of endogenous. Based on this, we then moved to evaluate their impact on Alms1/ retinal morphology and function:
in the Alms1/ eyes injected with triple vectors we observed a
modest, not signiﬁcant improvement in the outer nuclear layer
(ONL) thickness (Figure 8B), and in the electroretinogram a- (Figure 8C) and b-wave (Figure 8D) amplitudes between 5 and 7 months
of age (i.e., 4–6 months after gene delivery), which was lost at
9–11 months of age (Figures 8B–8D).
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Figure 7. Subretinal Administration of Triple AAV
Vectors Results in Full-Length CDH23 and ALMS1
Protein Expression in the Mouse Retina
(A) Western blot (WB) analysis of eyecup lysates from
C57BL/6J mice 3 months following subretinal injection of
triple AAV2/8 encoding for CDH23 under the control of
the ubiquitous CMV promoter. The arrows on the right
indicate the following products: #A, full-length proteins;
#C, probably from AAV 1 + 3. (B) WB analysis of eyecup
lysates from C57BL/6J mice 3 months following subretinal injection of triple AAV2/8 encoding for ALMS1
under the control of the ubiquitous short CMV promoter.
The arrow on the right indicates full-length ALMS1.
a-3xflag, WB with anti-3xflag antibodies; a-Dysferlin, WB
with anti-Dysferlin antibodies, used as loading control.
Neg, lysates of eyecups following injection with PBS. The
molecular weight ladder is depicted on the left; 200 mg of
proteins (A) or the whole-eyecup lysates (B) were loaded.

DISCUSSION
While AAV-mediated gene therapy is effective in animal models and
in patients with inherited blinding conditions,3–7,52 its application
to diseases affecting the retina and requiring transfer of sequences
larger than 5 kb is limited by the small cargo capacity of AAV. To
overcome this, dual AAV vectors, which exploit AAV genome tendency to concatemerize upon infection,25,53,54 have been developed
in order to expand AAV DNA transfer capacity to around 9 kb.
Here, we demonstrate both in vitro and in the mouse and pig retina
that similar strategies can be further implemented by including a third
vector in the system, thus expanding AAV transfer capacity to
approximately 14 kb.
Using the ubiquitous CMV as well as the PR- and RPE-speciﬁc IRBP
and VMD2 promoters, we showed that full-length gene reconstitution and expression is more efﬁcient in mouse RPE than in PRs.
This difference is probably due to a combination of the well-known
preferential ability of AAV to transduce RPE than PRs,9 as well as
of poor triple AAV genome recombination in PRs. Weak promoter
activity appears as a less likely explanation, as we observed robust
ED expression from the IRBP promoter using a single AAV vector
(Figure 5E). This low efﬁciency in PR transduction with triple
AAVs is similar to what we have previously observed with dual
AAV vectors,26 and is consistent with the low levels of homologous
recombination reported in post-mitotic neurons.45 It is important
to note that the spontaneous ﬂuorescence of the fusion protein ED
is weaker than the ﬂuorescence of the single native reporters (Figure S1). Thus, the actual number of PRs transduced by triple AAV
vectors may be higher than 3.6% observed in Figure 5A.
The percentage of mouse PR transduction is similar to the percentage
of HEK293 cells transduced by triple AAV vectors (2.78% of total cells
or 5.96% of transduced cells) despite the 25–50 times lower MOI predicted in the retina than used in in vitro infections. Indeed, OrtínMartínez et al.55 estimated that the total number of PRs in a mouse
retina is 6.4  106. Considering that we transduce, on average, onethird of the retina (which corresponds to about 2  106 PRs) we
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can infer that the MOI in the retina is between 1,000 and 2,000, as
opposed to 5  104 GC/cell used in vitro. The imaging data only
apparently differ from what we observe in the WB, where the levels
of transgene expression appear weaker in vivo than in vitro
(CDH23, Figure 4A versus Figure 7A; ALMS1, Figure 4C versus Figure 7B). Indeed, the in vivo WB analyses are performed on material
extracted from whole eyes as opposed to the imaging analysis, which
is conducted on the transduced area: thus, in WB, the transgenic protein from the transduced area is diluted within untransduced tissue.
Interestingly, while in mouse retina, ED expression observed with triple IRBP-ED-AAV vectors represented only 2% of that obtained with
single IRBP-ED-AAV, in pig retina this increased to 39%. This is
consistent with our previous results that the relative PR-EGFP expression obtained upon subretinal delivery of dual AAV vectors is 6% in
mice26 and 40% in pigs of that obtained with single AAV, which was
explained by the higher PR co-transduction rate of two independent
AAVs observed in pigs (74%) than in mice (24%).56 This could be due
to thicker physical barriers in the pig than in the mouse retina that
might limit vector diffusion, thus concentrating the vector in a
smaller area and maximizing co-infection of the same cells by multiple vectors. Also, species-speciﬁc differences in the efﬁciency of both
AAV2/8 transduction and/or vector intermolecular recombination
cannot be excluded. This result is particularly important, considering
that the pig retina is an excellent pre-clinical model with a size and
architecture more similar to the human than the mouse retina.10,57–61
An important concern for clinical use of multiple AAVs is the
possible generation of truncated proteins, which might affect both
safety and functionality of the treatment. We addressed this important issue by characterizing both transcripts and translated products
from triple AAV vectors in vitro and in the mouse retina. The in vitro
real-time qPCR and RNA-seq analyses showed that most of the
products expressed at high levels are predicted to be generated by
similar AAV genome concatemers between triple CDH- and
ALMS-AAVs (Figure 3). Interestingly, in addition to the products
from concatemers containing either simultaneously the promoter
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Figure 8. Alms1–/– Retinal Structure and Function following Subretinal Delivery of Triple AAV Vectors
(A) Immunohistochemical (IHC) analysis with anti-3xflag antibodies of retinal cryosections from C57BL/6J mice 2 months following subretinal injections of either triple AAV2/8
encoding for ALMS1 under the control of the PR-specific GRK1 promoter (top panels) or PBS (bottom panels). The pictures are representative of n = 4 injected eyes. The
scale bar (20 mm) is depicted in the figure. Merge, overlay of DAPI and ALMS1. ONL, outer nuclear layer; OS, outer segment. (B) Spectral domain optical coherence tomograms (SD-OCT) analysis of Alms1/ mice injected subretinally with either triple GRK1-ALMS-AAV vectors (white bars) in one eye or PBS in the contralateral eye (black
bars). Results are reported as means ± SE. (C and D) Electroretinographic analysis of a-wave (C) and b-wave (D) light responses of Alms1/ mice injected subretinally with
either triple GRK1-ALMS-AAV vectors (white bars) or PBS in the contralateral eye (black bars). Results are reported as means ± SE. Light intensity of 20 cd s/m2 (a-wave);
background white light of 50 cd s/m2 and light intensity of 20 cd s/m2 (b-wave).

and the polyadenilation signal (i.e., AAV 1 + 3 and AAV 1 + 2 + 3) or
the promoter alone (AAV 1 with or without AAV 2), we found high
levels of expression from AAV 2 in the case of ALMS1. It is possible
that, in this case, the ITR-mediated promotorial activity62 combined
with stability of the transcript results in high levels of aberrant transcript. However, the absence of a Kozak consensus sequence with a
close-by ATG suggests that this transcript should not be efﬁciently
translated.
Importantly, the translation of the various aberrant transcripts detected appears to be inefﬁcient, as only few truncated products, mostly
predicted from AAV 1 + 3 concatemerization, were observed in the
WB analysis of cells infected with triple AAVs. One exception appears
to be a protein product that is predicted to derive from CDH-AAV 3
that was detected, despite its low level of transcription, suggesting a
high stability of this product. Interestingly, the various alternative
CDH23 isoforms shown by RNA-seq (Figure S2A) may be responsible for the great number of protein products present in CDHAAV 1 + 3 sample. One important phenomenon that we have
observed is that most of the truncated products present when only
1 or 2 vectors were used for the infection decreased when the third
vector was added (Figures 2A–2C and 4A). This suggests that when

evaluating the potential toxicity of triple AAV vectors, this should
be done in the context of all vector components and not be extrapolated from combinations of single AAV.
The levels of aberrant proteins observed in vivo was even lower than
that observed in vitro (Figures 5B and 7). This is interesting, as some
of the transcripts detected by real-time qPCR in the mouse retinas
transduced with triple AAVs were more abundant than in cells
(primer sets A + B, A + D, B + C, B + D, C + D, and E + F) and suggests
a more stringent protein quality control in live animals than in
HEK293 cells. The only exception seems the detection of EGFPonly positive cells in retinal sections of animals injected with
ED-AAV 1 + 2 + 3 (Figure 5A). This could be the result of
products from ED-AAV 1 + 2 that are particularly stable and might
accumulate over the 2-month time of the in vivo but not of the shorter
in vitro experiments (Figure 2C). The low sensitivity of the WB with
anti-EGFP antibodies may explain why the product from ED-AAV
1 + 2 is only detected by direct ﬂuorescence analysis of retinal cryosections. In addition, the presence of protein products deriving
from alternative open reading frames (ORFs), which would not be detected with the set of antibodies used in this study, cannot be excluded
at this point.
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In agreement with the low levels of unexpected protein products in
the mouse retinas, no evident signs of toxicity were observed by optical coherence tomography analysis (data not shown) in animals injected 2 months before with either CDH- or ALMS-AAV 1 + 3, the
combination of viruses that produced the highest levels of truncated
products in vitro. Nevertheless, before considering the system for a
therapeutic use in humans, more efforts should be focused to evaluate
potential toxicity of truncated products, as well as strategies to eliminate them, such as the inclusion of degradation signals strategically
placed in the vectors, which we have recently demonstrated to be
effective at abolishing selectively truncated proteins from dual AAV
vectors.63
The possibility to further expand the dual AAV vectors to triple in order to express larger genes has been recently evaluated in mouse
muscle39,40 for dystrophin transduction, but with poor efﬁciency.
Although a direct comparison between the triple AAV vectors used
in that study and our triple AAV vectors is difﬁcult, the levels of
full-length transgene expression we achieve in the retina with triple
AAV vectors appear to be higher, as we are able to detect full-length
protein reconstitution by WB, in addition to ﬂuorescence analysis on
histological sections that were used for dystrophin detection in Lostal
et al.39 and Koo et al.40
The expression levels achieved in mice with triple ED-AAV compared
to single ED-AAV vectors are similar to those that we previously
observed with dual AAV vectors, both in the mouse and in the pig
retina,26 suggesting that, in the subretinal space, co-infection by multiple AAV vectors is favored.
If we consider that 3.6% of PRs are transduced by triple AAV vectors
following subretinal administration in mice (Figure 5A) and we
calculate the transgene expression levels per cell, we ﬁnd that the
102% of endogenous CDH23 achieved with triple CDH-AAVs corresponds to around 3,000% per cell. This is, however, due to the low
levels of endogenous CDH23 expression in mice (where it reaches
only 0.005% of GAPDH levels) but not in humans64 (http://retina.
tigem.it). If we, instead, consider ALMS1, whose endogenous levels
are higher than CDH23 and reach 0.22% of GAPDH, the levels of recombinant ALMS1, which are 7%–8% of endogenous, correspond to
approximately 200% per cell. In essence, the levels of CDH23 and
ALMS1 transgene expression from triple AAV vectors relative to
GAPDH are similar, while endogenous ALMS1 is expressed at higher
levels than CDH23 in mice.
Mice with ALMS146 but not CDH2365 deﬁciency present with PR
degeneration. To understand whether the transduction levels from
triple AAV vectors may be therapeutically relevant, we have treated
Alms1/ mice with subretinal injections of triple GRK1-ALMSAAV vectors, but, besides a transient improvement, we did not
observe any signiﬁcant amelioration of the phenotype. After conﬁrming that transgenic ALMS1 is properly expressed in PRs at levels
around 8% of endogenous, there could be several reasons that justify
this lack of therapeutic efﬁcacy: (1) as we have transferred the human
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ALMS1 transgene in Alms1/ mice, we cannot exclude that interspecies differences might be responsible for low therapeutic efﬁcacy;
(2) the non-cell-autonomous PR degeneration described in retinitis
pigmentosa66 may as well account for the lack of therapeutic effect;
and (3) as observed with triple ED-AAVs, only 3.6% of PRs are transduced (Figure 5A), and such fraction might not be sufﬁcient to detect
a signiﬁcant rescue. It is possible that higher levels of transduction
may improve the efﬁcacy of triple AAV vector. This could be obtained
(1) with higher vectors doses, (2) with more efﬁcient AAV serotypes
than those used here (i.e., AAV Y444, 500, 730F with mutated tyrosine residues),67,68 (3) by enlarging the transduced area with a
different injection technique (i.e., double injection) or by intravitreal
injection of highly penetrating serotypes such as AAV7m8,69 (4) by
using a more potent expression cassette than the one used in this
work, or (5) by co-injection of AAV transduction enhancers (i.e., proteasome inhibitors).70–72 Although these levels of rescue appear insufﬁcient in Alms1/ mice, it is important to note that, similar to what is
observed with dual AAV vectors, the level of pig PR ED transduction
by triple versus single AAV2/8 vectors is higher than in mice, which is
promising in view of future therapeutic applications, given the closer
similarity between human and pig than mouse retina.
Overall, our data demonstrate that triple AAV vectors drive large
gene reconstitution both in vitro and in vivo and that this approach
leads to the reconstitution of expression of large genes mutated in
IRDs like USHID or ALMS, thus extending AAV transfer capacity
up to 14 kb in the retina. This bodes well for the development of triple
AAV vectors for other retinal and non-retinal conditions, which
require transfer of such large sequences.

MATERIALS AND METHODS
Generation of AAV Vector Plasmids

The plasmids used for AAV vector production derived from the
pAAV2.173 plasmids that contain the ITRs of AAV serotype 2.
The EGFP-DsRed-AAV (ED-AAV) vectors were generated by cloning
Discosoma red ﬂuorescent protein (DsRed) CDS (675 bp), from the
pDsRed-Express2 plasmid (#632535; Clontech, Saint-Germain-enLaye, France) after the EGFP CDS (717 bp) of pAAV2.1-CMVEGFP plasmid73 separated by a 39-bp spacer and followed by a 3xﬂag
sequence and the bovine growth hormone polyadenylation signal
(bGHpA).
To generate triple ED-AAV vector plasmids, the ED CDS was split
into three constructs: the ﬁrst one (ED-AAV 1) containing the promoter and the N-terminal EGFP CDS74 (bp 1–393), the second one
(ED-AAV 2) containing the C-terminal EGFP CDS74 (bp 394–717)
plus the N-terminal DsRed CDS (FJ226077, bp 1–307), and the last
one (ED-AAV 3) containing the C-terminal DsRed CDS (FJ226077,
bp 308–675) plus the 3xﬂag.
As recombinogenic regions at the 30 end of ED-AAV 1 and 50 end
of ED-AAV 2, we used the AK sequence, derived from the
phage F1 genome (J02448.1, bp 5,850–5,926), which we previously
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demonstrated to be effective in the context of dual AAV vectors.26 As
a second recombinogenic region (at the 30 end of ED-AAV 2 and
50 end of ED-AAV 3), we used a 200-bp sequence (NM_000350.2,
bp 3,103–3,302) derived from the human ATP-binding cassette,
sub-family A 4 gene (ABCA4), which we found to be recombinogenic
in dual overlapping AAV vectors (AB200; data not shown).
To generate plasmids for triple CDH- and ALMS-AAV vectors, the
three fragments for each CHD23 (AF312024.1) and ALMS1 isoform 1
(NM_015120.4) were obtained by gene synthesis (MWG, now Euroﬁns Genomics, Ebersberg, Germany). CDH- and ALMS-AAV 1
contain the N-terminal CDS (CDH23, AF312024.1, bp 1–3,369;
ALMS1, NM_015120.4, bp 112–4,188); CDH- and ALMS-AAV 2
contain the body of the CDS (CDH23, AF312024.1, bp 3,370–6,712;
ALMS1, NM_015120.4, bp 4,189–8,452); and CDH- and ALMSAAV 3 contain the C-terminal CDS (CDH23, AF312024.1, bp
6,713–10,065; ALMS1, NM_015120.4, bp 8,453–12,618) followed by
a 3xﬂag tag and the bGHpA.
Note that the CDH23 CDS was split at a natural exon-exon junction,
while this was not possible for ALMS1, due to the exon length. Moreover, in both systems, fragment 1 and fragment 3 were designed in
order to generate out-of-frame transcripts in case of undesired
concatemerization.
The AK recombinogenic sequence was placed at the 30 of both
CDH- and ALMS-AAV 1 and at the 50 of CDH- and ALMSAAV 2. In the CDH23 expression system, we placed the AP
sequence (NM_001632.4, bp 1,802–1,516) derived from the human
placental alkaline phosphatase gene75 at the 30 of CDH-AAV 2 and
at the 50 of CDH-AAV 3, which results in levels of CDH23 expression higher than with AB200 (data not shown). Due to size
constraint, no recombination signals were placed at the 30 of
ALMS-AAV 2 nor at the 50 of the ALMS-AAV 3; full-length gene
reconstitution, in this case, relies exclusively on ITR-mediated
joining followed by splicing.
The splice donor (SD) and splice acceptor (SA) signals contained in
triple AAV vector plasmids are as follows: 50 -GTAAGTATCAAGGT
TACAAGACAGGTTTAAGGAGACCAATAGAAACTGGGCTTGT
CGAGACAGAGAAGACTCTTGCGTTTCT-30 (SD); 50 -GATAGG
CACCTATTGGTCTTACTGACATCCACTTTGCCTTTCTCTCCA
CAG-30 (SA).
The ubiquitous CMV promoter is the one contained in pAAV2.1CMV-EGFP;73 the ubiquitous shCMV promoter is the one described
in Pellissier et al.76; the PR-speciﬁc human IRBP (X53044.1, bp
2,603–2,837) and the human GRK1 promoter (AY327580.1, bp
1,793–2,087) have been both described to drive high levels of combined rod and cone PR transduction in various species;14,41,42 the
RPE-speciﬁc VMD2 promoter (NG_009033.1, bp 4,870–5,516) corresponds to the previously described EcoRI-XcmI promoter fragment43
and was ampliﬁed from human genomic DNA. The details of the cloning strategies as well as plasmid sequences are available upon request.

AAV Vector Production and Characterization

AAV vectors were produced by the TIGEM AAV Vector Core by triple transfection of HEK293 cells followed by two rounds of CsCl2 puriﬁcation.77 For each viral preparation, physical titers (GC/mL) were
determined by averaging the titer achieved by dot-blot analysis78 and
by PCR quantiﬁcation using TaqMan (Applied Biosystems, Carlsbad,
CA, USA).77 The probes used for dot-blot and PCR analyses were designed to anneal with the promoter for the 50 vector, the bGHpA region for the 30 vectors, and within the gene for the body vectors. The
length of probes varied between 200 and 700 bp.
Transfection and AAV Infection of HEK293 Cells

HEK293 cells were maintained in DMEM containing 10% fetal bovine
serum (FBS) and 2 mM L-glutamine (Gibco, Thermo Fisher Scientiﬁc,
Waltham, MA, USA). Depending on the experiment, cells were plated
in 6-well plates (1  106 cells/well), 24-well plate (2.5  105 cells/well),
or 8-chamber (1  105 cells/well) and transfected 16 hr later with the
plasmids encoding for the desired transgene using the calcium phosphate method (1 to 2 mg/1  106 cells); medium was replaced 4 hr later.
For AAV infection, plated cells were ﬁrst transfected with
1.5 mg/1  106 cells of pDeltaF6 helper plasmid, which contains the
Ad helper genes.79 After 4 hr, cells were washed once with serumfree DMEM and incubated with AAV2/2 vectors (MOI 5  104 GC/
cell of each vector) in a ﬁnal volume of 700 mL of serum-free DMEM.
Two hours later, 1.3 mL of complete DMEM was added to the cells.
To increase transgene expression, 7.5 mM Calpain inhibitor I ([PI]
A6185; Sigma-Aldrich, St. Louis, MO, USA), which is known to increase AAV-mediated transduction,80 was added either once after
infection with triple ED- and CDH-AAVs or daily after infection
with triple ALMS-AAVs.
Animal Models

Mice were housed at the Institute of Genetics and Biophysics animal
house (Naples, Italy) and maintained under a 12-hr light/dark cycle.
C57BL/6J mice were purchased from Harlan Italy SRL (Udine, Italy).
ALMS (referred as Alms1/) mice were imported from The Jackson
Laboratory. The mice were maintained by crossing heterozygous females with heterozygous males. The Alms1/ mouse harbors the
chemically-induced Alms1 c.1080 + 2T > C splice mutation
(exon 6-intron 6 splice junction) predicted to result in a frameshift
and truncation of ALMS1.51 The genotype of mice was conﬁrmed
by PCR analysis on genomic DNA (extracted from the mouse tail
tip) followed by DNA sequencing. The primers used for the PCR
ampliﬁcation are as follows:
Fw: 50 -GGTGCACAGAGTGAAAGAATTGC-30
Rev: 50 -ACTTACCAGTTAAGCCTTGTAGG-30 ,
which generate a product of 147 bp that was subsequently sequenced
using the Fw primer.
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The Large White female pigs (Azienda Agricola Pasotti, Imola, Italy)
used in this study were registered as purebred in the LWHerd Book of
the Italian National Pig Breeders’ Association and were housed at the
Centro di Biotecnologie A.O.R.N. Antonio Cardarelli (Naples, Italy)
and maintained under a 12-hr light/dark cycle.
Subretinal Injection of AAV Vectors in Mice and Pigs

This study was carried out in accordance with the Association for
Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research and with the Italian Ministry of Health regulation for animal procedures (Ministry of Health
authorization number 147/2015-PR). Surgery was performed under
general anesthesia, and all efforts were made to minimize animal
suffering. Mice (4 to 5 weeks old) were anesthetized with an intraperitoneal injection of 2 mL/100 g body weight of ketamine/xylazine,
then AAV2/8 vectors were delivered subretinally via a trans-scleral
trans-choroidal approach, as described by Liang et al.81 Eyes were injected with 1 mL of vector solution. The AAV2/8 doses (GC/eye) varied across different mouse experiments, as described in the Results
section. PI, at a ﬁnal concentration of 30 mM, was added to the vector
mix in mouse eyes intended for histology, real-time qPCR, and in
3 out of 15 eyes injected with triple CDH-AAV vectors and destined
for WB analysis.
Subretinal delivery of AAV2/8 vectors to the pig retina was performed
as previously described.10 Eyes (n = 3) were injected with 100 mL of
AAV2/8 vector solution. The AAV2/8 dose was 1  1011 GC of
each vector/eye; thus, co-injection of triple AAV vectors resulted in
a total of 3  1011 GC/eye.
WB Analysis

Samples (HEK293 cells plated in 6-well plates or eyecups [cups +
retinas]) for WB analysis were lysed in radio-immunoprecipitation
assay (RIPA) buffer (50 mM Tris-HCl [pH 8.0], 150 mM NaCl,
1% NP40, 0.5% Na-deoxycholate, 1 mM EDTA, 0.1% SDS
[pH 8.0]) to extract ED, CDH23, and ALMS1 proteins from
HEK293 cells and eyecups. Lysis buffers were supplemented with
protease inhibitors (Complete Protease inhibitor cocktail tablets;
Roche, Basel, Switzerland) and 1 mM phenylmethylsulfonyl. After
lysis, ED, CDH23, and ALMS1 samples were denatured at 99 C
for 5 min in 1 Laemmli sample buffer. For ALMS1, 1 Laemmli
sample buffer was supplemented with 4 M urea. Lysates were separated by 12% (ED samples), 6% (CDH23 samples), or gradient
(#4561086; Bio-Rad, Hercules, CA, USA) 4%–15% (ALMS1 samples) SDS-PAGE.
The antibodies and dilutions used for immunoblotting are as follows:
anti-EGFP (1:1,000, ab1218; Abcam, Cambridge, UK); anti-3xﬂag
(1:1,000, A8592; Sigma-Aldrich, St. Louis, MO, USA); anti-CDH23
(1:500, sc-166005, Santa Cruz Biotechnology, Dallas, TX, USA);
anti-ALMS1 (1:1,000, polyclonal; ab4306, Abcam, Cambridge, UK);
anti-b Tubulin (1:3,000, T5201; Sigma Aldrich, St. Louis, MO,
USA); anti-Filamin A (1:1,000, #4762; Cell Signaling Technology,
Danvers, MA, USA); anti-Dysferlin (1:500, Dysferlin, clone Ham1/
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7B6, MONX10795; Tebu-bio, Le Perray-en-Yveline, France); antib-Actin (1:1,000, NB600-501; Novus Biological, Littleton, CO, USA).
Notably, the epitope to which the monoclonal anti-EGFP antibodies
were raised has not been disclosed by the company; however, we
deduced that it maps to the C terminus of EGFP based on the pattern
observed in the WB analysis in Figure 2B.
The quantiﬁcation of ED bands detected by WB was performed using
ImageJ software (http://rsbweb.nih.gov/ij/); to compare data across
different experiments, in each WB, the average intensity of the bands
deriving from single AAV-transduced eye was set as 1, and the intensity of triple AAV transduced eye was divided by that of single AAVtransduced eye and calculated accordingly.
Histology and Light and Fluorescence Microscopy

To evaluate ED expression in vitro, HEK293 cells, plated in 8-chambers at a density of 1  105, were infected as previously described. Seventy-two hours post-infection, cells were washed once with PBS, ﬁxed
for 7 min with 4% paraformaldehyde (PFA) in PBS, washed three
times with PBS, and mounted with Vectashield with DAPI (Vector
Lab, Peterborough, UK). Cells were analyzed under the Axio
Observer Z1 (Carl Zeiss, Oberkochen, Germany) equipped with
ZEN software (Carl Zeiss) and using appropriate excitation and
detection settings for EGFP, DsRed, and DAPI.
To evaluate transgene expression in histological sections, C57BL/6J
mice were injected subretinally with triple AAV vectors (supplemented with PI at a ﬁnal concentration of 30 mM). Two months later,
mice were sacriﬁced and eyes were ﬁxed in 4% paraformaldehyde
overnight and inﬁltrated with 30% sucrose overnight; the cornea
and the lens were then dissected, and the eyecups were embedded
in optimal cutting temperature compound (O.C.T. matrix; Kaltek,
Padua, Italy). Ten-micrometer-thick serial retinal cryosections were
cut along the horizontal meridian, progressively distributed on slides,
and mounted with Vectashield with DAPI (Vector Lab, Peterborough, UK). Then, the cryosections were analyzed under the confocal
LSM-700 microscope (Carl Zeiss, Oberkochen, Germany) using
appropriate excitation and detection settings.
For assessment of PR transduction in mouse retinal cryosections
following triple ED-AAV administration, a single section/eye within
the transduced area was selected; the whole slice was acquired at
40 magniﬁcation and then analyzed using ImageJ software
(http://rsbweb.nih.gov/ij/). A minimum of 600 PRs, identiﬁed by
DAPI staining, were counted for each eye. PRs with signal compatible
with EGFP and DsRed co-expression were unequivocally identiﬁed
based on their identical shape on picture micrographs of the same
ﬁeld.
In the case of ﬂuorescent IHC staining of ALMS1, sections were
washed in PBS for 10 min and were permeabilized and blocked
with 0.3% Triton X-100, 5% next-generation sequencing (NGS),
3% BSA in PBS for 3 hr, then the sections were pre-treated with
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Avidin/Biotin (SP-2001, Vector Lab, Peterborough, UK) according to
manufacturer’s instructions. Sections were incubated overnight
with anti-3xﬂag antibodies (1:200 F1804 Sigma-Aldrich, St. Louis,
MO, USA). Endogenous peroxidase were blocked with 0.3%
hydrogen peroxide (H1009, Sigma-Aldrich, St. Louis, MO, USA).
Signal was developed using the Vectastain ABC kit (PK-6200 Vector
Laboratories, CA, USA) followed by the SuperBoost Tyramide signal
ampliﬁcation (B40942, Thermo Fisher Scientiﬁc, Waltham, MA,
USA) according to the manufacturer’s instructions. Stained sections
were mounted with Vectashield with DAPI (Vector Laboratories,
CA, USA). Cryosections were analyzed under the confocal LSM700 microscope (Carl Zeiss, Oberkochen, Germany) and acquired
at 63 magniﬁcation.

HEK293 cells and mouse GAPDH (mGAPDH) for eyecups and
retinas).
RNA-Seq Libraries Preparation and Sequencing

A total of 47.5 ng of RNA was used as input for the synthesis of cDNA
with the SMART-Seq v4 Ultra Low Input RNA Kit for Sequencing
(Takara Bio USA, Mountain View, CA, USA). Manufacturer suggested protocol was followed, with minor modiﬁcations. The second
strand synthesis of cDNA was performed by replacing the SMARTSeq v4 Oligo with custom primers speciﬁc for the transgenes of interest (CDH23 oligo, 50 -AAGCAGTGGTATCAACGCAGAGTacttgtt
gatctccgaagataccc-30 ; ALMS1 oligo, 50 -AAGCAGTGGTATCAACG
CAGAGTtagtggtggaggaagtagaggag-30 [bp in capital letters belong to
the RNA-seq adaptor]).

Cytofluorimetric Analysis

HEK293 cells, plated in 6- or 24-well plates, were washed once with
PBS, detached with trypsin 0.05% EDTA (Thermo Fisher Scientiﬁc,
Waltham, MA USA), washed twice with PBS, and resuspended in
PBS 5% FBS, 2.5 mM EDTA. Cells were analyzed on a BD FACS
ARIA III (BD Biosciences, San Jose, CA, USA) equipped with BD
FACSDiva software (BD Biosciences) using appropriate excitation
and detection settings for EGFP and DsRed. Thresholds for ﬂuorescence detection were set on not infected cells, and a minimum of
10,000 cells/sample were analyzed.

Seventy-ﬁve pg of cDNA generated with SMART-Seq v4 Kit were
used for library preparation using the NEXTERA XT DNA Library
Preparation kit (Illumina, San Diego, CA, USA), following the suggested protocol.
Samples were sequenced using NextSeq 500/550 Mid Output v2 kit in
a 150 + 150 paired-end run. The data were deposited in GEO:
GSE107173.
RNA-Seq Analysis

RNA Extraction, cDNA Production, and Reverse Transcription
Analysis

Total RNA was extracted using the RT-PCR RNeasy MiniKit
(QIAGEN, Milan, Italy) from either HEK293 cells plated in 6- or
24-well plates and infected or not with triple AAV vectors or mouse
eyecups or retina. RNA (500 ng from cells or eyecups and 360 ng
from retina) was submitted to DNase I digestion (RNase Free
DNase set; QIAGEN) and 20 mL cDNA was generated using the
SuperScript III Reverse Transcriptase kit (Thermo Fisher Scientiﬁc,
Waltham, MA, USA) using oligo dT primers. For each sample,
the same amount of RNA did not receive the retrotranscriptase
enzyme and was used as a control for genomic DNA contamination. Primers for real-time qPCR were designed using the bioinformatic program “Primer Blast” (https://www.ncbi.nlm.nih.gov/
tools/primer-blast/) and purchased from Euroﬁns Genomics (Euroﬁns Genomics, Ebersberg, Germany; Table S1). Serial dilutions of
the cDNAs obtained from cells infected with either triple CDHor ALMS-AAV 1 + 2 + 3 were used to measure the primer efﬁciency, which was between 1.75 and 2.25 for all primer sets shown
in Figure 3B. SybrGreen real-time qPCR kit was purchased from
Roche (Roche, Monza, Italy) and used following the manufacturer’s
protocol on the LyghtCycler 96 system (Roche). Five microliters of
diluted cDNA (1:25 to 1:50 for in vitro experiments and 1:5 for the
in vivo experiments) and 10 pmol of primers were used for PCR in a
total volume of 20 mL. Thermal cycling for all genes initiated with
an initial denaturation step at 95 C for 5 min, followed by 45 cycles
with denaturation at 95 C for 10 s, annealing at 60 C for 20 s, and
extension at 72 C for 20 s. Expression data were then normalized
versus the corresponding housekeeping genes (h-b-ACTIN for

Sequence reads were trimmed using Trim Galore! software (https://
www.bioinformatics.babraham.ac.uk/projects/trim_galore/) to remove adaptor sequences and low-quality end bases and then analyzed
using the “new tuxedo” software suite.82 The idea was to generate a
custom reference with a “genomic” sequence of the three vector inserts where to align the reads. The expected full-length transcript
was used as known reference, but the aligner software was allowed
to introduce new splicing junctions and generate also alternative transcripts if supported by reads (Figure S2).
First, the custom reference sequence was built to perform the viral
vector library sequences alignment. For each transgene, the
sequence of the three vector inserts were pasted sequentially side
by side, separated by a stretch of N bases as spacers to simulate a
“genomic” sequence and then added to the human genome (build
hg19) as separate contigs. The ITR ends were not included to reduce
the possibility of aberrant splicing junctions due to mis-aligned
repeated reads. The relative coordinates of the actual CDSs of
each transgene were used as reference of a single transcript
composed of three exons. The ﬁrst exon start and the last exon
end bases were deﬁned to coincide respectively with the beginning
of the speciﬁc PCR primer and the expected transcription stop
signal, in order to reproduce the expected drop in coverage of the
aligned reads due to library construction, to minimize the generation of alternative predicted transcripts only differing from the
reference by the start or end coordinates.
Then the analysis was performed following the protocol described in
Pertea et al.82 Reference-guided alignment was performed with
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HISAT283 followed by transcript assembly with Stringtie.84 The assembly generated for each sample can be slightly different due to
the actual coverage of exons and reads spanning exon-exon junctions,
so the individual assemblies of each sample were merged into a common consensus with the Stringtie merge function to make them comparable. The expression levels of each transcript of the assembled
consensus were then estimated with a ﬁnal run of Stringtie used to
count reads supporting each transcript without allowing the annotation of any further isoform. The R/Biocondictor package Ballgown85
was then used to visualize results and extract the raw counts and
normalization was performed with DESeq.86
To estimate the relative abundance of each annotated alternative isoform, their normalized counts were divided by the corresponding fulllength one and the ratios were averaged among three replicate
samples.
Spectral Domain Optical Coherence Tomography

Spectral domain optical coherence tomography (SD-OCT) images
were obtained using the Bioptigen Spectral Domain Ophthalmic Imaging System (SDOIS; Envisu R2200, Bioptigen, Morrisville, NC,
USA). ALMS mice were anesthetized and pupils were dilated by
applying 1–2 drops of topical 0.5% tropicamide (Visufarma, Rome,
Italy). To prevent corneal desiccation during the procedure, topical
lubricant eye drops (Recugel; Bausch & Lomb, Rochester, NY,
USA) were applied bilaterally with a small brush. Mice were positioned into the animal imaging mount and rodent alignment stage
(AIM-RAS; Bioptigen, Morrisville, NC, USA); the laser source was
placed in front of the mouse, and images were acquired by the
InVivoVue Clinic software (Bioptigen, Morrisville, NC, USA). Three
images, one central, one superior, and one inferior to the optic nerve,
were taken from each eye. ONL thickness was manually measured
three times from each OCT scan image and averaged.
Electrophysiological Recordings

For electroretinographic analyses, ALMS mice were dark-adapted for
3 hr. Mice were anesthetized and positioned in a stereotaxic apparatus, under dim red light. Their pupils were dilated with a drop of
0.5% tropicamide (Visufarma, Rome, Italy), and body temperature
was maintained at 37.5 C. Light ﬂashes were generated by a Ganzfeld
stimulator (CSO, Costruzione Strumenti Oftalmici, Florence, Italy).
The electrophysiological signals were recorded through gold-plate
electrodes inserted under the lower eyelids in contact with the cornea.
The electrodes in each eye were referred to a needle electrode inserted
subcutaneously at the level of the corresponding frontal region.
The different electrodes were connected to a two-channel ampliﬁer.
After completion of responses obtained in dark-adapted conditions
(scotopic), the recording session continued with the purpose of dissecting the cone pathway mediating the light response (photopic).
To minimize the noise, different responses evoked by light were averaged for each luminance step. The maximal scotopic response of rods
and cones was measured in dark conditions (scotopic) with two
ﬂashes of 0.7 Hz and a light intensity of 20 cd s/m2, photopic cone responses were isolated in light conditions with a continuous back-
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ground white light of 50 cd s/m2, with 10 ﬂashes of 0.7 Hz and a light
intensity of 20 cd s/m2.
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Figure S1. The EGFP-DsRed-3xflag (ED) protein is less fluorescent than the corresponding native
EGFP and DsRed reporters.
Fluorescence analysis of HEK293 cells transfected with plasmids encoding either native EGFP (pEGFP),
native DsRed (pDsRed) or the EGFP-DsRed-3xflag reporter protein construct (pED). EGFP, native EGFP
fluorescence; DsRed, native DsRed fluorescence; merge: overlay of EGFP and DsRed. The scale bar (200
µm) is depicted in the figure.

Figure S2. Alternative transgene isoforms annotated by RNA-Seq analysis.
For each transgene, the alternative isoforms are plotted below the full-length transcript. The relative abundance is quantified by
mean and standard error of the normalized count ratio vs the full-length among 3 replicates.

A

S1

S2

T1 T2

Neg

S3 S4

T3 T4 T5

Neg

S5 S6

75 kDa -

75 kDa -

75 kDa -

55 kDa -

55 kDa -

55 kDa -

α-3xflag
α-Tubulin

S8 S9

α-3xflag

α-3xflag

α-Tubulin

α-Tubulin

T9 T10 T11 Neg

S7

S10 S11 S12 T12 T13 T14

T6 T7 T8

Neg

Neg

75 kDa -

75 kDa -

55 kDa 55 kDa α-3xflag

α-3xflag
α-Tubulin

B

α-Tubulin

1,8

Band intensity relative to
average single

1,6
1,4
1,2
1
0,8
0,6
0,4
0,2
0
S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12
Single ED-AAV

T1 T2 T3 T4 T5 T6 T7 T8 T9 T10T11T12T13T14
Triple ED-AAVs

Figure S3. Comparison between single and triple CMV-ED-AAV2/8 transduction in mouse retina.
(A) WB analysis of eyecup lysates from C57BL/6J 2 months following subretinal injection of single and triple AAV2/8 vectors encoding
for ED under the control of the ubiquitous CMV promoter. α-3xflag, WB with anti-3xflag antibodies; α-β-Tubulin, WB with anti-βTubulin antibodies, used as loading control. Neg, lysates from eyecups following injection with PBS. The molecular weight ladder is
depicted on the left, 100-150 µg of proteins were loaded. The arrow on the left indicates the full-length ED. S1-12: lysates from eyecups
injected subretinally with single CMV-ED-AAV: T1-14: lysates from eyecups injected subretinally with triple CMV-ED-AAVs. Neg,
lysates of eyecups following injection with PBS.
(B) Densitometric values of ED bands in (A). To compare data across different experiments, in each WB the average intensity of the
bands deriving from single AAV transduced eye was set as 1 and the intensity of triple AAVs transduced eye was divided by that of
single AAV transduced eye and calculated accordingly. S1-12: lysates from eyecups injected subretinally with single CMV-ED-AAV.
T1-14: lysates from eyecups injected subretinally with triple CMV-ED-AAVs.
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Figure S4. Comparison between single and triple IRBP-ED-AAV2/8 transduction in mouse retina.
(A) WB analysis of eyecup lysates from C57BL/6J 2 months following subretinal injection of single and triple AAV2/8 vectors encoding
for ED under the control of the PR specific IRBP promoter. α-3xflag, WB with anti-3xflag antibodies; α-β-Tubulin, WB with anti-βTubulin antibodies, used as loading control. Neg, lysates from eyecups following injection with PBS. The molecular weight ladder is
depicted on the left, 200 µg of proteins were loaded. The arrow on the left indicates the full-length ED. S1-6, lysates from eyecups
injected subretinally with single IRBP-ED-AAV. T1-8, lysates from eyecups injected subretinally with triple IRBP-ED-AAVs. Neg,
lysates of eyecups following injection with PBS.
(B) Densitometric values of ED bands in (A). To compare data across different experiments, in each WB the average intensity of the
bands deriving from single AAV transduced eye was set as 1 and the intensity of triple AAVs transduced eye was divided by that of
single AAV transduced eye and calculated accordingly. S1-6: lysates from eyecups injected subretinally with single IRBP-ED-AAV. T18: lysates from eyecups injected subretinally with triple IRBP-ED-AAVs.

Primer name

Sequence

CDH A

ctgccaactggggtatcttc

CDH B

ctgttggtaagcggcatact

CDH C

tcagcacgtgactggaattt

CDH D

acatcgtcgggattgtagcga

CDH E

gtaagtggccaccagttccct

CDH F

agaccatgacggcgactata

mCDH wt Forw

catcgtggccaaggatgacac

mCDH wt rev

gaatgctctgggaggtcgct

ALMS A

ctcctctacttcctccaccac

ALMS B

cttctacagccacaccgaga

ALMS C

tgcctcttcagtcagatggg

ALMS D

gccagcgtaggtgtgttcaa

ALMS E

cttctggctttgccttcgtc

ALMS F

aggttccttgggacgactac

mALMS wt forw

taggacgtgaccgtggatact

mALMS wt rev

gccttgtggacttcgtaagc

h𝛽-ACTIN forw

gcgagaagatgacccagatc

h𝛽-ACTIN rev

ggatagcacagcctggatag

mGAPDH forw

agcaaggacactgagcaagag

mGAPDH rev

gcagcgaactttattgatggt

Table S1.
List of primers used for Real-Time quantitative PCR. Fw: forward primer; Rev:
reverse primer; wt: wild type.

